Stereotactic Ablative Radiotherapy (SABR) in Patients with Medically Inoperable Peripheral Early Stage Lung Cancer: Outcomes for the First UK SABR Cohort

Survival After Stereotactic Body Radiation Therapy for Clinically Diagnosed or Biopsy-Proven Early-Stage NSCLC: A Systematic Review and Meta-Analysis

“…6 Some authors even reported a lower survival of clinically diagnosed patients undergoing SBRT compared to patients with histologically confirmed disease, possibly reflecting a higher incidence of comorbidities. 11,12 Such confounders might complicate comparing oncological outcomes between surgery and SBRT for early-stage NSCLC. In this systematic review and meta-analysis, we therefore assess survival outcomes after SBRT from both comparative and noncomparative cohort studies in patients with clinically versus biopsy-proven earlystage NSCLC.…”

Cone-beam computed tomography in lung stereotactic ablative radiation therapy: predictive parameters of early response

“…1,2,[18][19][20] All patients were treated with a BED $100 Gy, assuming an a/b value of 10 Gy for the tumour, according to literature, 21 except for one case in which a schedule with a BED of 95 Gy was delivered because of prior contralateral pneumonectomy.…”

A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer

“…43 The final study patient reported as grade 5 toxicity had no data regarding the cause of death, and the patient died within 30 days of treatment. 46 Grade 3 and 4 toxicity reports range between 2.7% and 27% of patients. Pneumonitis, dyspnoea, chest pain and pneumonia being the most commonly reported toxicity.…”